New drug cocktail aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT04317105
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will receive the combination. Researchers will monitor side effects and check if tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
copanlisib, nivolumab, ipilimumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have specific genetic changes, potentially slowing or shrinking the cancer.
What could go wrong
This is an early-phase trial with only 54 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States